Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 11, 2009

View Archived Issues

JAK2 inhibitor SB-1518 shows promise against hematological malignancies

Responses seen in CLL patients given cenersen added to chemo-immunotherapy

Phase I studies of products utilizing ImmunoGen's TAP technology presented at ASH meeting

Nabi Biopharmaceuticals begins phase I/II trial of antigens in PentaStaph vaccine

Neurocrine reports results from phase II trial of elagolix in endometriosis

Bayer Schering reports results from phase II trial of riociguat in pulmonary hypertension

Stallergenes reports 3-year results from phase III VO53.06 clinical trial of Oralair

Cytokinetics and GSK to terminate collaboration and license agreement

Actelion presents update on clinical development of ACT-128800

Sanofi-aventis and Alopexx sign collaboration agreement for human monoclonal antibody

Gruenenthal discloses novel bradykinin 1 receptor antagonists in development

CSIR claims the discovery of novel antimalaria agents

Gla formation inhibitors described by Daiichi Sankyo as anticoagulants

Arete Therapeutics presents sEH inhibitors as antihypertensives

Phase I results show oncolytic virotherapy with DWP-418 feasible, well tolerated

Tolerability and pharmacokinetic evaluations of ceftriaxone completed in ALS patients

Novel glucokinase activators discovered at Takeda

Novel PHD inhibitors presented by Janssen for anemia therapy

Banyu presents MCH-R1 antagonists for treatment of obesity and diabetes

Sangart initiates phase IIa study of oxygen therapeutic agent MP-4OX

Mologen applies for phase II clinical study for cancer drug MGN-1703

RegeneRx Biopharmaceuticals reports results from phase I trial of RGN-352

Bionomics and partners to conduct phase II BNC-105 trial in mesothelioma

Oxagen completes recruitment in phase IIb dose-finding trial of OC-000459 in asthma

Celgene to acquire Gloucester Pharmaceuticals

Amarin Neuroscience withdraws MAA for ethyl eicosapent soft gelatine capsules

Protalix Biotherapeutics submits NDA to FDA for taliglucerase alfa for Gaucher's disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...